The effects of diadenosine polyphosphates on the cardiovascular system

Cardiovascular Research

Volumn 42, Issue 1, 1999, Pages 15-26

  Flores, Nicholas A ^a   Stavrou, Brigitte M ^a   Sheridan, Desmond J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Bradycardia; Haemodynamics; K ATP channel; Platelets; Vasoconstriction dilation

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; DIADENOSINE POLYPHOSPHATE; NITRIC OXIDE; PROSTACYCLIN; PURINE P2 RECEPTOR;

BRADYCARDIA; CARDIOVASCULAR RESPONSE; CHEDIAK HIGASHI SYNDROME; CHEMICAL STRUCTURE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REFRACTORY PERIOD; HEART RATE; HEMODYNAMICS; HYPERTENSION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; VASOCONSTRICTION; VASODILATATION;

ACTION POTENTIALS; ANIMALS; CARDIOVASCULAR SYSTEM; DINUCLEOSIDE PHOSPHATES; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; POTASSIUM CHANNELS; RECEPTORS, PURINERGIC; SECOND MESSENGER SYSTEMS; VASCULAR RESISTANCE; VASODILATION;

EID: 0032920026     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00004-8     Document Type: Review

References (82)

1. Baxi M.D., Vishwanatha J.K. Diadenosine polyphosphates: their biological and pharmacological significance. J Pharmacol Toxicol Methods. 33:1995;121-128.
2. 2X-purinoceptors in rat urinary bladder. Br J Pharmacol. 112:1994;1151-1159.
3. Hoyle C.H.V. Pharmacological activity of adenine dinucleotides in the periphery: possible receptor classes and transmitter function. Gen Pharmacol. 21:1990;827-831.
4. Schlüter H., Tepel M., Zidek W. Vascular actions of diadenosine phosphates. J Auton Pharmacol. 16:1996;357-362.
5. Ripoll C., Martin F., Rovira J.M., et al. Diadenosine polyphosphates. A novel class of glucose-induced intracellular messengers in the pancreatic β-cell. Diabetes. 45:1996;1431-1434.
6. Bochner B.R., Lee P.C., Wilson S.W., Cutler C.W., Ames B.N. AppppA and related adenylylated nucleotides are synthesized as a consequence of oxidative stress. Cell. 37:1984;225-232.
7. 4-tetraphosphate: A pleiotropically acting alarmone? Cell. 34:1983;711-712.
8. Lee P.C., Bochner B.R., Ames B.N. AppppA, heat shock stress, and cell oxidation. Proc Nat Acad Sci USA. 80:1983;7496-7500.
9. Rubino A., Burnstock G. Possible role of diadenosine polyphosphates as modulators of cardiac sensory-motor neurotransmission in guinea-pigs. J Physiol. 495:1996;515-523.
10. 2+ transients in guinea-pig brain via receptors distinct from those for ATP. J Physiol. 504:1997;327-335.
11. 4A on coronary resistance and autacoid release of intact rabbit hearts. Am J Physiol. 260:1991;H1692-H1697.
12. Stavrou B.M., Sheridan D.J., Flores N.A. Cardiac electrophysiological and haemodynamic effects of diadenosine polyphosphates in the isolated perfused guinea-pig heart (abstract). J Physiol. 509P:1998;150P-151P.
13. nA), a novel class of signalling molecules? FEBS Lett. 427:1998;157-163.
14. 4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA. 89:1992;2370-2373.
15. 4A) in mammalian cells in levels varying widely with proliferative activity of the tissue: A possible positive "pleiotypic activator" Proc Natl Acad Sci USA. 73:1976;3984-3988.
16. 3A) in human platelets. Biochem Biophys Res Commun. 115:1983;253-260.
17. Busse R., Ogilvie A., Pohl U. Vasomotor activity of diadenosine triphosphate and diadenosine tetraphosphate in isolated arteries. Am J Physiol. 254:1988;H828-H832.
18. 4A) on platelet aggregation in unfractionated human blood. Blut. 51:1985;405-413.
19. 4A in human plasma. Purification and characterization of a glycoprotein complex with 5′-nucleotide phosphodiesterase activity. Eur J Biochem. 149:1985;119-127.
20. Mateo J., Rotllan P., Marti E., et al. Diadenosine polyphosphate hydrolase from presynaptic plasma membranes of Torpedo electric organ. Biochem J. 323:1997;677-684.
21. 3A in human serum. Identification of isoenzymes and their partial characterization. Eur J Biochem. 169:1987;385-388.
22. Ogilvie A., Antl W. Diadenosine tetraphosphatase from human leukemia cells. Purification to homogeneity and partial characterization. J Biol Chem. 258:1983;4105-4109.
23. 4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets. Biochem J. 208:1982;737-742.
24. 3A in whole blood. The dinucleotides are long-lived signal molecules in the blood ending up as intracellular ATP in the erythrocytes. Eur J Biochem. 173:1988;241-245.
25. Lerman B.B., Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation. 83:1991;1499-1509.
26. 3A) by porcine aortic endothelial cells. Circ Res. 59:1986;362-366.
27. 99mTc-labeled nucleotides as tumor-seeking radiodiagnostic agents. Proc. Natl. Acad. Sci. USA. 81:1984;918-921.
28. Delaney S.M., Blackburn G.M., Geiger J.D. Diadenosine polyphosphates inhibit adenosine kinase activity but decrease levels of endogenous adenosine in rat brain. Eur J Pharmacol. 332:1997;35-42.
29. K(Ach) by diadenosine polyphosphates in guinea-pig atrial myocytes. J Physiol. 512:1998;407-420.
30. 4-tetraphosphate receptor is at the cell surface of heart cells. Biochemistry. 32:1993;14009-14014.
31. 4-tetraphosphate hydrolase is present in human erythrocytes, leukocytes and platelets. Int Biochem Cell Biol. 27:1995;201-206.
32. nA, by chromaffin cells in culture. Arch Biochem Biophys. 297:1992;176-183.
33. Pintor J., King B.F., Ziganshin A.U., Miras-Portugal M.T., Burnstock G. Diadenosine polyphosphate-activated inward and outward currents in follicular oocytes of Xenopus laevis. Life Sci. 59:1996;PL179-PL184.
34. 2-purinoceptors in the guinea-pig left atrium by diadenosine polyphosphates. Br J Pharmacol. 118:1996;1294-1300.
35. 4A) to rat liver cell membranes. Biochem J. 314:1996;687-693.
36. 2 purinergic receptors for diadenosine polyphosphates in the nervous system. Gen Pharmacol. 26:1995;229-235.
37. 3A) mediates human platelet aggregation by liberation of ADP. Biochem Biophys Res Commun. 118:1984;704-709.
38. 4A) in heavy platelets. Consequences for in vitro studies with human platelets. Blut. 54:1987;193-200.
39. Brown A.S., Martin J.F. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest. 24:(Suppl. 1):1994;9-15.
40. 4A and Other Dinucleoside Polyphosphates. 1992;229-273 CRC Press, Boca Raton, FL.
41. 4A and Other Dinucleoside Polyphosphates. 1992;29-61 CRC Press, Boca Raton, FL.
42. Schlüter H., Offers E., Brüggemann G., et al. Diadenosine phosphates and the physiological control of blood pressure. Nature. 367:1994;186-188.
43. Harrison M.J., Brossmer R., Goody R.S. Inhibition of platelet aggregation and the platelet release reaction by α,ω diadenosine polyphosphates. FEBS Lett. 54:1975;57-60.
44. 4-tetraphosphate. Proc Natl Acad Sci USA. 89:1992;11056-11058.
45. 4-tetraphosphate: A novel antiplatelet agent. Proc Natl Acad Sci USA. 94:1997;4034-4039.
46. Tepel M., Bachmann J., Schlüter H., Zidek W. Diadenosine polyphosphate-induced increase in cytosolic free calcium in vascular smooth muscle cells. J Hypertens. 13:1995;1686-1688.
47. Ralevic V., Hoyle C.H.V., Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. J Physiol. 483:1995;703-713.
48. 2-purinoceptors in the cardiovascular system. Circulation. 84:1991;1-14.
49. Chen Z.-P., Levy A., Lightman S.L. Nucleotides as extracellular signalling molecules. J Neuroendocrinol. 7:1995;83-96.
50. Gordon J.L. Extracellular ATP: effects, sources and fate. Biochem J. 233:1986;309-319.
51. van der Giet M., Khattab M., Börgel J., Schlüter H., Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol. 120:1997;1453-1460.
52. 4A. Biochim Biophys Acta. 1010:1989;151-159.
53. Nees S. Coronary flow increases induced by adenosine and adenine nucleotides are mediated by the coronary endothelium: a new principle of the regulation of coronary flow. Eur Heart J. 10:(Suppl. F):1989;2835.
54. Kikuta Y., Sekine A., Tezuka S., et al. Intravenous diadenosine tetraphosphate in dogs. Cardiovascular effects and influence on blood gases. Acta Anaesthesiol Scand. 38:1994;284-288.
55. Humphrey S.M., Holliss D.G., Cartner L.A. Influence of inhibitors of ATP catabolism on myocardial recovery after ischaemia. J Surg Res. 43:1987;187-195.
56. Kengatharan M., Thiemermann C., Vane J.R. Analysis of the cardiovascular responses to diadenosine pentaphosphate in the anaesthetised rat (abstract). Br J Pharmacol. 113:1994;62P.
57. Nakae I., Takahashi M., Takaoka A., et al. Coronary effects of diadenosine tetraphosphate resemble those of adenosine in anesthetized pigs: involvement of ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 28:1996;124-133.
58. 1-adenosine receptors. Br J Pharmacol. 119:1996;835-844.
59. 4-tetraphosphate. J Biol Chem. 266:1991;6915-6918.
60. + channel. Biochem Pharmacol. 54:1997;219-225.
61. Olsson R.A., Pearson J.D. Cardiovascular purinoceptors. Physiol Rev. 70:1990;761-845.
62. Fredholm B.B., Abbracchio M.P., Burnstock G., et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 18:1997;79-82.
63. Jacobsen K.A., van Rhee A.M., Moro S. Pharmacology of purinergic receptors. http://mgddk1.niddk.nih.gov.8000/pharmacol.html 1996. Accessed 24th October 1997 and 16th September 1998.
64. Communi D., Boeynaems J.-M. Receptors responsive to extracellular pyrimidine nucleotides. Trends Pharmacol Sci. 18:1997;83-86.
65. Fredholm B.B., Abbracchio M.P., Burnstock G., et al. Nomenclature and classification of purinoceptors. Pharmacol Rev. 46:1994;143-156.
66. Miras-Portugal M.T., Castro E., Mateo J., Pintor J. The diadenosine polyphosphate receptors: P2D purinoceptors. Ciba Found Symp. 198:1996;35-47.
67. Alexander SPH, Peters JA, editors. Receptor and Ion Channel Nomenclature Supplement. 8th ed. Trends Pharmacol Sci 1997.
68. 4-tetraphosphate mouse heart receptor. Biochem Biophys Res Commun. 200:1994;749-755.
69. 4-tetraphosphate receptor. Biochemistry. 32:1993;3119-3123.
70. 4-tetraphosphate receptor. Biochemistry. 32:1993;1264-1269.
71. 4A binding protein by photoaffinity labeling. Biochemistry. 33:1994;14601-14607.
72. Pintor J., Gualix J., Miras-Portugal M.T. Diinosine polyphosphates, a group of dinucleotides with antagonistic effects on diadenosine polyphosphate receptor. Mol Pharmacol. 51:1997;277-284.
73. Flores N.A., Botchway A.N.S., Stavrou B.M., Sheridan D.J. Cardiac electrophysiological effects of platelet-derived substances. Exp Physiol. 84:1999;253-274.
74. Flores N.A., Sheridan D.J. The pathophysiological role of platelets during myocardial ischaemia. Cardiovasc Res. 28:1994;295-302.
75. Flores N.A. Platelet activation during myocardial ischaemia: a contributory arrhythmogenic mechanism. Pharmacol Ther. 72:1996;83-108.
76. Pantely G.A., Bristow J.D. Adenosine. Renewed interest in an old drug. Circulation. 82:1990;1854-1856.
77. Hori M., Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension. 18:1991;565-574.
78. Ely S.W., Berne R.M. Protective effects of adenosine in myocardial ischaemia. Circulation. 85:1992;893-904.
79. Janse M.J., Wit A.L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 69:1989;1049-1169.
80. Agha A., Schlüter H., Konig S., et al. A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. J Vasc Res. 29:1992;281-289.
81. Apitz-Castro R., Cruz M.R., Ledezma E., et al. The storage pool deficiency in platelets from humans with the Chédiak-Higashi syndrome: study of six patients. Br J Haematol. 59:1985;471-483.
82. 4-tetraphosphate deficiency in blood platelets of the Chédiak-Higashi syndrome. Blood. 66:1985;735-737.